CYCC
NASDAQ
Cyclacel Pharmaceuticals, Inc. - Common Stock
Healthcare
· Biotechnology
$1.52
+0.04 (+2.7%)
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$15.7M
ROE
-164.4%
Margin
-18150.0%
D/E
0.00
Beta
0.17
52W
$3–$598
Price Chart
Fundamentals Trend
| Metric | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -740.0% | — | — | -164.4% | -41.8% | -164.4% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -81425.0% | -19570.0% | -26074.4% | — | — | -18150.0% |
| Gross Margin | — | — | — | — | — | 37.7% |
| D/E Ratio | 0.00 | — | — | 0.00 | 0.00 | 0.00 |
| Current Ratio | 1.07 | 0.77 | 0.59 | 5.60 | 5.77 | 5.60 |
Key Ratios
ROA (TTM)
-156.0%
P/S (TTM)
211.64
P/B
4.4
EPS (TTM)
$-121.75
CF/Share
$-1.50
52W High
$597.60
52W Low
$3.08
$3.08
52-Week Range
$597.60
How does CYCC compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
CYCC valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
211.6
▲
1547%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
4.5
▲
81%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
CYCC profitability vs Biotechnology peers
ROE
-164.4%
▼
144%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-18150.0%
▼
6230%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
37.7%
▼
52%
below
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-156.0%
▼
234%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
CYCC financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
5.6
▲
26%
above
peers
(4.4)
vs Peers
vs Industry
Below avg
Beta
0.2
▼
82%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
CYCC fundamentals radar
CYCC
Peer median
Industry
CYCC profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CYCC vs peers: key metrics
Latest News
No related news yet